- Home
- CRT vs ALVR Comparison
CRT vs ALVR Comparison
Compare CRT & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- ALVR
- Stock Information
- Founded
- CRT 1991
- ALVR 2013
- Country
- CRT United States
- ALVR United States
- Employees
- CRT N/A
- ALVR N/A
- Industry
- CRT Oil & Gas Production
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRT Energy
- ALVR Health Care
- Exchange
- CRT Nasdaq
- ALVR Nasdaq
- Market Cap
- CRT 60.9M
- ALVR 48.8M
- IPO Year
- CRT 1992
- ALVR 2020
- Fundamental
- Price
- CRT $10.66
- ALVR $9.63
- Analyst Decision
- CRT
- ALVR
- Analyst Count
- CRT 0
- ALVR 0
- Target Price
- CRT N/A
- ALVR N/A
- AVG Volume (30 Days)
- CRT 27.5K
- ALVR 22.4K
- Earning Date
- CRT 01-01-0001
- ALVR 03-14-2025
- Dividend Yield
- CRT 8.04%
- ALVR N/A
- EPS Growth
- CRT N/A
- ALVR N/A
- EPS
- CRT 1.13
- ALVR N/A
- Revenue
- CRT $7,711,133.00
- ALVR N/A
- Revenue This Year
- CRT N/A
- ALVR N/A
- Revenue Next Year
- CRT N/A
- ALVR N/A
- P/E Ratio
- CRT $9.44
- ALVR N/A
- Revenue Growth
- CRT N/A
- ALVR N/A
- 52 Week Low
- CRT $8.88
- ALVR $7.96
- 52 Week High
- CRT $17.72
- ALVR $24.15
- Technical
- Relative Strength Index (RSI)
- CRT 50.85
- ALVR 45.63
- Support Level
- CRT $10.23
- ALVR $9.55
- Resistance Level
- CRT $11.36
- ALVR $10.41
- Average True Range (ATR)
- CRT 0.34
- ALVR 0.44
- MACD
- CRT 0.01
- ALVR 0.05
- Stochastic Oscillator
- CRT 38.05
- ALVR 22.77
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States based trust. Its principal asset is the net profits interests. The net profits interests are derived from producing royalty, overriding royalty interests, and working interests properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.